AnaptysBio, Inc. Common Stock
$54.31
-$0.37 (-0.68%)
$53.62Day Range$54.80
Key Statistics
Market Cap
$1.61B
Shares Outstanding
29.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 26, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$54.44
Day High
$54.80
Day Low
$53.62
Volume
394.1K
VWAP
$54.16
Prev Close
$54.68
Transactions
--
Acc. Volume
--
About AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
PHARMACEUTICAL PREPARATIONSSIC 2834104 employees10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121858-362-6295IPO Jan 26, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001370053
- Composite FIGI
- BBG0026ZDHR0
- Share Class FIGI
- BBG0026ZDHT8
- Ticker Root
- ANAB
- SIC Code
- 2834
About AnaptysBio, Inc. Common Stock (ANAB) Stock
AnaptysBio, Inc. Common Stock (ANAB) closed the 2026-09-16 session at $54.31, down 0.68% versus the previous close (-0.37). The stock opened at $54.44 and traded between $53.62 and $54.80 during that session. Session trading volume was 394K shares. The volume-weighted average price (VWAP) is $54.16.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
AnaptysBio, Inc. Common Stock has a market capitalization of $1.61 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ANAB is listed on the XNAS exchange. The company employs approximately 104 people. AnaptysBio, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2017-01-26.
On this page you can find market ANAB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.